News | PET-CT | June 12, 2017

FDA Clears Biograph Horizon Flow Edition PET/CT System From Siemens Healthineers

System’s FlowMotion continuous bed motion scanning technology enables personalized PET exam protocols based on patient’s anatomy

Siemens Healthineers announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow edition, a cost-competitive positron emission tomography/computed tomography (PET/CT) system that features the company’s revolutionary FlowMotion continuous bed motion scanning technology. With products such as the Biograph Horizon Flow edition, as well as a new name that underlines the company’s pioneering spirit and engineering expertise, Siemens Healthineers – the separately managed healthcare business of Siemens AG – is helping to enable healthcare providers worldwide to meet current challenges and excel in their respective environments.

Initially introduced on the company’s premium Biograph mCT Flow PET/CT platform in 2013, FlowMotion continuous bed motion technology differs from conventional step-and-shoot PET/CT scanning in that it enables personalized exam protocols based on patient anatomy. These protocols can be configured based on the radiology department’s most commonly scanned indications to support standardization. With the extension of FlowMotion continuous bed motion technology to Biograph Horizon Flow edition scanners, users can define up to four distinct scanning regions, each with a different bed speed. Additionally, specific exam reconstructions can be applied to each scanning region or to multiple regions.  Biograph Horizon Flow edition facilitates high-resolution reconstructions and respiratory gating, which can help improve the ability of clinicians to detect lesions.

In addition to FlowMotion continuous bed motion technology, Biograph Horizon Flow edition includes HD•Chest – another popular feature previously found only on the company’s Biograph mCT family of PET/CT systems – which acquires and processes motion-frozen chest scans five times faster than standard respiratory gating techniques.

“With the addition of Biograph Horizon Flow edition to the Siemens Healthineers PET/CT portfolio, customers tasked with reaching a certain price point no longer need to make compromises in the PET/CT technology they offer patients,” said Doug Darrow, Vice President of Molecular Imaging at Siemens Healthineers North America. ‘The Biograph Horizon Flow edition is the ideal https://www.itnonline.com/channel/pet-ct not only for progressive community hospitals but also for satellite campuses of large healthcare networks that are looking to provide the same premium continuous bed motion technology as their flagship facilities.”

For more information: www.siemens.com/healthineers

Related Content

The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
The Neal Awards recognize the best in business-to-business editorial across standalone and integrated media channels

Editor Dave Fornell tries his hand at virtual reality at RSNA 2017.

News | Radiology Business | March 28, 2018
Imaging Technology News has been recognized with an award nomination from the Jesse H.
News | Radiology Business | March 08, 2018
Scranton Gillette Communications’ Imaging Technology News (ITN) was recently named a 2018 Azbee Award finalist in five...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Enterprise imaging is evolving to address the problem — to find and assemble relevant information so that accurate diagnoses can be made efficiently and effectively
Feature | Enterprise Imaging | March 06, 2018 | By Jeff Zagoudis
Physicians are struggling with too much of a good thing. They have never had so much information about their patients....
Sponsored Content | Videos | Women's Health | February 27, 2018
Fujifilm details its latest innovations in women's health including its ASPIRE Cristalle mammography system with...
Sponsored Content | Videos | Pediatric Imaging | February 22, 2018
FUJIFILM Medical Systems U.S.A., Inc. and FUJIFILM SonoSite Inc., are offering a full-suite pediatric solutions...
Sponsored Content | Videos | Flat Panel Displays | February 21, 2018
This 5 megapixel, high-brightness color monitor has the high-definition display necessary for breast imaging.
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Overlay Init